582 results on '"Rüther, E."'
Search Results
2. Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia
3. Correction to: Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia
4. Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial
5. What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?
6. Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder
7. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI
8. Sleep Disorders and Portal-Systemic Encephalopathy Following Transjugular Intrahepatic Portosystemic Stent Shunt in Patients with Liver Cirrhosis : Relation to Plasma Tryptophan
9. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders
10. Comparison of skeletal muscle strength between cardiac patients and age-matched healthy controls
11. Genome-wide significant risk factors for Alzheimerʼs disease: role in progression to dementia due to Alzheimerʼs disease among subjects with mild cognitive impairment
12. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study
13. Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients
14. Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing
15. Seizures during antidepressant treatment in psychiatric inpatients—results from the transnational pharmacovigilance project “Arzneimittelsicherheit in der Psychiatrie” (AMSP) 1993–2008
16. Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias
17. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin
18. CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies
19. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome
20. Narcolepsy: Increased L–PGDS (β–trace) levels correlate with excessive daytime sleepiness but not with cataplexy
21. Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder
22. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome
23. Erythropoietin: a candidate compound for neuroprotection in schizophrenia
24. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia: A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks
25. Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder
26. Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy
27. Salivary, total plasma and plasma free cortisol in panic disorder
28. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale
29. A novel MRI-biomarker candidate for Alzheimerʼ disease composed of regional brain volume and perfusion variables
30. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients
31. Outcome of suicidal patients with schizophrenia: results from a naturalistic study
32. Psychiatric Aspects of Portal-Systemic Encephalopathy
33. Rebound insomnia after hypnotic withdrawal in insomniac outpatients
34. Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide
35. Long-term modulation of presynaptic 5-HT-output: Experimentally induced changes in cortical 5-HT-transporter density, tryptophan hydroxylase content and 5-HT innervation density
36. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners
37. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa
38. Quetiapine improves sleep in acute mania: a case series: O125
39. Effects of chronic treatment with methadone and naltrexone on sleep in addicts
40. Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports
41. What treatments do patients with panic disorder and agoraphobia get?
42. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS)
43. 99mTc-HMPAO-SPECT in the diagnosis of senile dementia of Alzheimer's type — a study under clinical routine conditions
44. Effects of clozapine on CSF homovanillic acid in spasmodic torticollis
45. Somnologics - Medicines for the Treatment of Sleep Disorders
46. DAS OBSTRUKTIVE SCHLAFAPNOE-SYNDROM ZUR EVALUIERUNG OXIDATIVEN STRESSES: V 01.04
47. Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus)
48. The metabolic fate of infusedl-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites
49. V(44) NARKOLEPSIE: ERHÖHTE L-PGDS (ß-TRACE)-SPIEGEL KORRELIEREN MIT DER HYPERSOMNIA, ABER NICHT MIT DER KATAPLEXIE
50. V(2) EINSCHLAFSCHWIERIGKEITEN BEI KINDERN UND JUGENDLICHEN IN KINDERARZTPRAXEN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.